Home › Funds › Bain Capital Life Sciences Investors, LLC › KYTX
Bain Capital Life Sciences Investors, LLC position in KYTX
KYVERNA THERAPEUTICS INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 1,312,000 shares of KYTX (KYVERNA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$8.9M, representing 0.61% of its reported portfolio and ranking #19 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed KYTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's KYTX position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in KYTX in Q1 2024 at 3,163,868 shares (US$78.6M). Across 11 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,312,000 shares valued at US$8.9M — a reduction of -1,573,000 shares quarter over quarter.. Notable position changes include a 55% trim in Q3 2026 (shares fell 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 3.16M | $78.59M | New |
| Q2 2024 | 3.37M | $25.26M | Add |
| Q3 2024 | 3.37M | $16.47M | Hold |
| Q4 2024 | 3.37M | $12.60M | Hold |
| Q1 2025 | 3.37M | $6.50M | Hold |
| Q2 2025 | 3.37M | $10.34M | Hold |
| Q3 2025 | 3.37M | $20.21M | Hold |
| Q4 2025 | 3.11M | $29.23M | Reduce |
| Q1 2026 | 3.11M | $26.84M | Hold |
| Q2 2026 | 2.88M | $25.71M | Reduce |
| Q3 2026 | 1.31M | $8.92M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KYTX and 13F data
KYTX (KYVERNA THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in KYTX — the largest reported positions include GordonMD Global Investments LP (US$30.7M), GILEAD SCIENCES, INC. (US$28.1M), AIGH Capital Management LLC (US$24.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYTX
- GordonMD Global Investments LP 4.52M sh · $30.74M · Q3 2026
- GILEAD SCIENCES, INC. 4.13M sh · $28.06M · Q3 2026
- AIGH Capital Management LLC 3.65M sh · $24.82M · Q3 2026
- Insight Holdings Group, LLC 989.05K sh · $8.81M · Q2 2026
- MBB PUBLIC MARKETS I LLC 614.48K sh · $5.47M · Q2 2026
- Propel Bio Management, LLC 700.60K sh · $4.76M · Q3 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held KYTX?
Bain Capital Life Sciences Investors, LLC has disclosed KYTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Bain Capital Life Sciences Investors, LLC's current position in KYTX?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 1.31M shares of KYTX (KYVERNA THERAPEUTICS INC), valued at $8.92M, representing 0.61% of its reported portfolio and ranking #19.
Has Bain Capital Life Sciences Investors, LLC been buying or selling KYTX?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC reduced its position in KYTX.
Which other funds hold KYTX?
Other major institutional holders of KYTX include GordonMD Global Investments LP, GILEAD SCIENCES, INC., AIGH Capital Management LLC, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.